Effect modifiers in a randomized phase III trial of low-dose tamoxifen in breast preinvasive disease.
Andrea De Censi(Ente Ospedaliero Ospedali Galliera), Bernardo Bonanni(European Institute of Oncology), Antonio Ponti(Piedmont Reference Center for Epidemiology and Cancer Prevention), Matteo Lazzeroni(European Institute of Oncology), Davide Corradengo(Ente Ospedaliero Ospedali Galliera), Franca Avino(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Marcella Gulisano(Azienda Industriali Municipali di Vicenza (Italy)), Tania Buttiron Webber(Ente Ospedaliero Ospedali Galliera), Maria Grazia Paquola(Ospedale Regina Margherita), Silvia Caviglia(Ente Ospedaliero Ospedali Galliera), Fabio Falcini(Centro di Riferimento Oncologico), Laura Cortesi(Azienda Ospedaliero-Universitaria di Modena), Aliana Guerrieri‐Gonzaga(European Institute of Oncology), Luca Boni(Ospedale Policlinico San Martino), Anna Cariello(Azienda Unità Sanitaria Locale Della Romagna), Maria Digennaro, Graziella Pinotti(Medica (Italy)), Harriet Johansson(European Institute of Oncology), Matteo Puntoni(University of Parma)
Cited by 3
Related Papers
Association analysis identifies 65 new breast cancer risk loci
|Nature|2017|1.6k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k